Journal of Patient-Reported Outcomes (Aug 2023)

Measuring dengue illness intensity: Development and content validity of the dengue virus daily diary (DENV-DD)

  • Amy M. Jones,
  • Todd L. Saretsky,
  • Charlotte Panter,
  • Jane R. Wells,
  • Frances White,
  • Verity Smith,
  • Helen Kendal,
  • Kevin Russell,
  • Madelyn Ruggieri,
  • Shawna R. Calhoun,
  • Adam Gater,
  • Justin O’Hagan,
  • Kathryn B. Anderson,
  • Valerie A. Paz-Soldan,
  • Amy C. Morrison,
  • Lisa Ware,
  • Michelle Klick,
  • Stephen Thomas,
  • Morgan A. Marks

DOI
https://doi.org/10.1186/s41687-023-00624-5
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 18

Abstract

Read online

Abstract Background Dengue is the most prevalent arboviral infection causing an estimated 50–60 million cases of febrile illness globally per year, exacting considerable disease burden. Few instruments exist to assess the patient illness experience, with most based on healthcare provider assessment, lacking standardization in timepoints and symptom assessment. This study aimed to evaluate the content validity of the novel ‘Dengue Virus Daily Diary (DENV-DD)’, designed to measure symptom intensity and disease burden within outpatient infant to adult populations. Methods The Dengue Illness Index Report Card was used as a foundation to create the DENV-DD, consisting of patient- and observer-reported outcome (PRO/ObsRO) instruments. In two South American dengue-endemic communities, qualitative combined concept elicitation and cognitive debriefing interviews were conducted among individuals and caregivers of children with symptomatic laboratory-confirmed dengue. Interviews were conducted across two rounds allowing DENV-DD modifications. A small-scale quantitative assessment of the DENV-DD was also conducted with data from an independent Dengue Human Infection Model (DHIM) to generate early evidence of feasibility of DENV-DD completion, instrument performance and insight into the sign/symptom trajectory over the course of illness. Results Forty-eight participants were interviewed (20 adults, 20 older children/adolescents with their caregivers, 8 caregivers of younger children). A wide spectrum of signs/symptoms lasting 3–15 days were reported with fever, headache, body ache/pain, loss of appetite, and body weakness each reported by > 70% participants. DENV-DD instructions, items and response scales were understood, and items were considered relevant across ages. DHIM data supported feasibility of DENV-DD completion. Conclusions Findings demonstrate content validity of the DENV-DD (PRO/ObsRO instruments) in dengue-endemic populations. Psychometric and cultural validity studies are ongoing to support use of the DENV-DD in clinical studies.

Keywords